ReviewImmunology and allergy clinics of North America2012
Dapsone in the management of autoimmune bullous diseases.
Review in Immunology and allergy clinics of North America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 43 citations in OpenAlex.
- Antioxidant Polymeric and Non-Polymeric Nanoformulations for the Treatment of Autoimmune Diseases.Current issues in molecular biology · 2026Review
- Antagonizing FcαR1 (CD89) as treatment in IgA-mediated chronic inflammation and autoimmunity.Frontiers in immunology · 2023Article
- Unusual cause of persistent dyspnea in a patient with nephrotic syndrome: dapsone-induced methemoglobinemia.CEN case reports · 2021Article
- Comorbidities and Treatment Strategies in Bullous Pemphigoid: An Appraisal of the Existing Litterature.Frontiers in medicine · 2018Review
- Steroid-sparing effect and toxicity of dapsone treatment in giant cell arteritis: A single-center, retrospective study of 70 patients.Medicine · 2016Observational
- Erlotinib augmentation with dapsone for rash mitigation and increased anti-cancer effectiveness.SpringerPlus · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Dapsone is used in the treatment of autoimmune bullous diseases (AIBD), a group of disorders resulting from autoimmunity directed against basement membrane and/or intercellular adhesion molecules on cutaneous and mucosal surfaces. This review summarizes the limited published data evaluating dapsone as a therapy for AIBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.